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bioequivalence study samples for estimation of MRT and DMRT in healthy human subjects.
ª 2010 King Saud University. Production and hosting by Elsevier B.V.Table 1a Experimental condition for liquid chromatography.
Sr. No. Chromatographic
parameters
Optimized parameters
1 Mobile phase delivery Isocratic mode
2 Mobile phase 92:8 (v/v) acetonitrile: 3 mM
ammonium formate, pH adjusted
to 5.0 with formic acid
3 Analytical column Betasil-C18, 100 · 3.0 mm,
3.0 lm
4 Mobile phase ﬂow rate 0.5 ml/min
5 Autosampler tray
temperature
10 C
6 Column temperature 45 C
7 Injection volume 3 ll
8 Autosampler rinsing
volume
500 ll before and after injection
9 Analytical run time 1.8 min
 
 Open access under CC BY-NC-ND license.1. Introduction
Mirtazapine (MRT) is a tetracyclic piperazinoazepine, which
has a different structure from any other currently used antide-
pressant. MRT is a potent antagonist of 5-HT2 and 5-HT3
receptors. MRT has no signiﬁcant afﬁnity for the 5-HT1A
and 5-HT1B receptors. MRT is a potent antagonist of histamine
(H1) receptors, a property that may explain its prominent sed-
ative effects. MRT is a moderate peripheral alpha1 adrenergic
antagonist, a property that may explain the occasional ortho-
static hypotension reported in association with its use. MRT
is a moderate antagonist at muscarinic receptors, a property
that may explain the relatively low incidence of anti-cholinergic
side effects associated with its use. MRT is extensively metabo-
lized after oral administration (Physicians Desk Reference
(PDR), 2007; Baumann et al., 2006; SNaRIs et al., 2000). Ma-
jor pathways of biotransformation are demethylation and
hydroxylation followed by glucuronide conjugation. In vitro
data from human liver microsomes indicate that cytochrome
2D6 and 1A2 are involved in the formation of the 8-hydroxy
metabolite of MRT, whereas cytochrome 3A is considered to
be responsible for the formation of the N-desmethyl and N-
oxide metabolite. DMRT is the only pharmacologically active
metabolite, which contributes only 3–6% to the total pharma-
codynamic proﬁle of MRT (Physicians Desk Reference (PDR),
2007, Baumann et al., 2006; SNaRIs et al., 2000).
Several chromatographic methods including LC-UV (Dodd
et al., 2000; de Santana et al., 2004; Romiguieres et al., 2002),
LC–DAD (Duverneuil et al., 2003; Titier et al., 2003), LC-ﬂuo-
rescence detector (Maris et al., 1999; Ptaek et al., 2003), CE
detector (de Santana et al., 2008; Mandrioli et al., 2004) and
LC–MS/MS (de Santana et al., 2008, 2010; Wang et al., 2009;
Pistos et al., 2004; Hong et al., 2008) have been developed to
measure MRT and DMRT in biological ﬂuids. LC-UV, LC–
DAD, LC-ﬂuorescence detector and CE methods are inade-
quate because of low sensitivity (LLOQ> 0.5 ng/ml), high
injection volume (>5 ll), long chromatographic run time
(>2.5 min) and large volume of plasma (>0.5 ml) required
for analysis. Hence these methods allow determination of only
75–300 samples in a day, which is not enough for day to day
analysis and commercial utilization in pharmacokinetics stud-
ies. Reported LC–MS/MS methods (de Santana et al., 2008,
2010; Wang et al., 2009) are less sensitive having LLOQ 1.25,
62 and 10 ng/ml and chromatographic run time >2.4 min per
sample. Another LC–MS/MS method (Pistos et al., 2004) is en-
ough sensitive but requires run time >2.5 min, sample extrac-
tion involves laborious steps like evaporation and
reconstitution. Although LC–MS/MS method reported for
quantitation of MRT in human plasma by Hong et al., 2008 is
sufﬁciently sensitive, this method requires laborious extraction
procedure like LLE involving time-consuming and error-prone
solvent evaporation and reconstitution steps and long run time.
This paper describes the development and validation of an
LC–MS/MS method for the quantiﬁcation of MRT and
DMRT in human plasma, which reduces sample preparationand analysis time relative to other commonly employed tech-
niques (LLE) and has a limit of quantitation (LOQ) 0.1 ng/
ml. Imipramine was used as an internal standard.
2. Experimental
2.1. Chemicals, reagents, standards
Pharmaceutical grade ofMRT, DMRT and IS were kindly sup-
plied by Vardha Biotech (Mumbai, Maharashtra, India) were
certiﬁed to contain 99.45%, 99.65% and 96.90% respectively,
and used without further puriﬁcation. Organic solvents used
where of gradient grade and were obtained from (Ranbaxy,
Delhi, India). Water was obtained from a Milli-Q Gradient
water puriﬁcation system (Millipore, Bedford, Massachusetts,
USA). Formic acid was of suprapur grade and obtained from
Merck (Darmstadt, Germany). Ammonium formate used for
mobile phase preparation was molecular biology-tested grade
from Sigma–Aldrich (Steinheim, Germany). Oasis SPE car-
tridges were obtained from Waters (Massachusetts, Ireland).
Control human plasma was obtained from Green Cross Labo-
ratory and was stored below 70 C prior to use.
Stock solutions of MRT, DMRT and IS were prepared in
methanol at free base concentration of 1 mg/ml, respectively.
Secondary and working standard solutions were prepared
from stock solutions by dilution with water. These diluted
working standard solutions were used to prepare the calibra-
tion curve and quality control (QC) samples in human plasma.
A nine-point standard calibration curves for MRT and
DMRT were prepared by spiking the blank plasma with
appropriate amount of MRT and DMRT. The calibration
curves were ranged from 0.1 to 100.0 ng/ml. Quality-control
samples for MRT and DMRT were prepared in three concen-
tration levels: 0.3 ng/ml LQC; 30 ng/ml MQC and 75 ng/ml
HQC, in a manner similar to preparation of standard solutions
from the stocks solution.
Figure 1 Full scan spectra and product ion spectra of mirtazapine.
Table 1b Experimental condition for mass spectrometric detection.
Sr. No. ESI source optimized parameter
1 Spray voltage 3500 V
2 Sheath gas 40 (arbitrary units)
3 Auxiliary gas 20 (arbitrary units)
4 Capillary temperature 350 C
5 Collision gas pressure (argon) 1.5 mTorr
6 Scan type Selected reaction monitoring (SRM)
7 Polarity for analytes Positive ion polarity
Scan parameter for analyte Parent Product Scan time CE Resolution Tube lens
(m/z) (m/z) (s) (V) Q1 PW Q3 PW (V)
MRT 266.1 195.1 0.2 23 0.7 0.7 104
DMRT 252.01 180 0.2 26 0.7 0.7 98
IS 281.07 86.1 0.2 21 0.7 0.7 74
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A 0.2 ml aliquot of human plasma (volunteers, CS and QC
samples) was mixed with 25 ll of IS working solution
(100 ng/ml of IS). The sample mixture was loaded into an Oa-
sis HLB (1 cm3/30 mg), an extraction cartridge that was pre-
conditioned with 1.0 ml methanol followed by 1.0 ml water.
The extraction cartridge was washed with 2 ml water followed
by 1.0 ml 10% methanol. MRT, DMRT and IS were eluted
with 0.7 ml of acetonitrile; 3.0 ll of the eluate was injected into
LC–MS/MS system.
2.3. LC–MS/MS
High-performance liquid chromatography was performed with
a Prominence pump, autosampler, autoinjector, and column
oven from Shimadzu (Kyoto, Japan). Mass spectrometry wasperformed with a TSQ Quantum triple-quadrupole mass spec-
trometer by Thermo Finnigan (Thermo Electron, San Jose,
CA, USA). All LC and MS/MS conditions were controlled
by LCquan software, version 2.5.6.
Compounds were separated on a 100 mm · 3.0 mm, 3.0 lm
particle, Betasil-C18 reversed-phase column (Thermo Electron
Corporation). The column temperature was 45 C and the
autosampler tray temperatures were 10 C. The mobile phase
was (92:8, v/v) acetonitrile: 3 mM ammonium formate, pH ad-
justed to 3.5 with formic acid, at a ﬂow rate of 0.5 ml/min. The
chromatographic condition and mass spectrometric parame-
ters are presented in Tables 1a and 1b (Figs. 1–3).
The LCquan software provided a standard method for cal-
culations for quantitative analysis. Peak-area ratios of the
calibrators were used in linear regression analysis with a
weighting factor of 1/x2. The response curve was used to calcu-
late the concentration of calibrators, QC, and stability samples.
Figure 2 Full scan spectra and product ion spectra of desmethyl mirtazapine.
Figure 3 Full scan spectra and product ion spectra of imipramine.
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3.1. Method development
The objective of this method was to develop and validate (Guid-
ance for Industry, BioanalyticalMethod Validation, USDepart-
ment Health and Human Services, Food Drug administration
Center for Drug Evaluation and Research (CDER), Centre
for Veterinary Medicines ((CVM), 2001) a rapid, sensitive andsimple assay method for the extraction and quantiﬁcation of
MRTandDMRT.Duringmethod development different detec-
tion, chromatographic, and sample-extraction condition were
evaluated to achieve maximum response and good peak shape.
Initially, tuning of the MS conditions in both positive and
negative modes was performed for MRT, DMRT and the
IS, and the response was found to be much higher in posi-
tive-ionization mode. Use of Betasil-C18 (100 mm · 3.0 mm
i.d., 3.0 lm) column enabled use of 0.5 ml/min ﬂow rate, which
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try and signal of analytes. In several initial trials with ammo-
nium formate and methanol for mobile phase optimization
the response was low when pH of the ammonium formate
was 3.5. The pKa values of MRT and DMRT are 7.1 but
peak shape of analyte was not good. When 3 mM ammonium
formate of pH 3.5 was used with acetonitrile good peak shape
and improved signal were obtained with low background
noise, resulting in higher speciﬁcity. The maximum backpres-
sure during analysis was 48 bars. The optimum column oven
temperature was 45 C, which resulted in symmetrical peaks.
In order to achieve cleanliness in extract, solid-phase extrac-
tion was optimized for extraction of analytes from plasma. Both
the analytes and IS showed good retention when eluated with
acetonitrile. In order to eliminate time-consuming and error-
prone solvent evaporation and reconstitution steps for concen-
tration of samples after elution with acetonitrile, the elution vol-
ume of acetonitrile was reduced to 0.7 ml to concentrate the
sample in eluate. The optimized extraction condition enabled
to reduce processing and analysis time. The sample injected
3.0 ll, avoided column backpressure and ESI source contami-
nation during sample analysis in clinical studies.3.2. Method validation
3.2.1. Selectivity and speciﬁcity
The speciﬁcity of the method was investigated by comparing
chromatograms obtained from six different sources of plasma.
The limit of detection (LOD) observed at 0.010 ng/ml concen-
tration for both analytes. The SRM transitions 266.10ﬁ
195.10, 252.01ﬁ 180.00 and 281.07ﬁ 86.10 were chosen for
quantiﬁcation of MRT, DMRT and IS, respectively. The area
observed at the retention time of MRT, DMRT was much less
than 20% that of the LLOQ (ng/ml) area (Figs. 4 and 5).Figure 4 Representative chromatograms for extracted blank pl3.2.2. Calibration curves
Five linearity curves containing nine non-zero concentrations
were analyzed. The calibration curves were appeared linear
and were well described by least squares lines. A weighting fac-
tor of 1/concentration i.e. 1/x2 was chosen to achieve homoge-
neity of variance for MRT and DMRT. The accuracy and
precision observed for the back calculated concentrations of
ﬁve linearity from CS-1 to CS-9 are presented in Tables 2a
and 2b. The correlation coefﬁcient were P0.9994 (n= 5) for
MRT and DMRT.3.2.3. Sensitivity
The LLOQ is deﬁned as the lowest concentration of the cali-
bration standard yielding accuracy ±20% RE and precision
of 620% RSD. The intra-run precision of LLOQ plasma sam-
ples containing MRT and DMRT were 3.85% and 7.44%,
respectively. The mean intra-run accuracy of LLOQ plasma
containing MRT and DMRT were 112.00% and 101.00%,
respectively.3.2.4. Recovery
Recovery of MRT and DMRT was calculated by comparing
the peak area of the analyte from extracted plasma standard
with that obtained from unextracted standard at the same
concentration for quality-control samples containing 0.3,
30.0 and 75.0 ng/ml, respectively. The percent mean recovery
for MRT and DMRT were observed 88.56 and 89.45, respec-
tively. The mean recovery of IS was 92.50% at concentration
100.0 ng/ml.
3.2.5. Precision and accuracy
The intra-assay precision and accuracy were calculated in six
replicates analyses for MRT and DMRT at four concentrationasma: (a) mirtazapine; (b) desmethyl mirtazapine and (c) IS.
Figure 5 Representative chromatograms for extracted LLOQ: (a) mirtazapine 0.100 ng/ml; (b) desmethyl mirtazapine 0.100 ng/ml and
(c) extracted IS 100 ng/ml.
Table 2a Summary of calibration curves for mirtazapine with back calculated concentrations.
Linearity Mirtazapine, concentration in ng/ml
CS-1 CS-2 CS-3 CS-4 CS-5 CS-6 CS-7 CS-8 CS-9
0.1 0.2 2.0 10.0 20.0 40.0 60.0 80.0 100.0
1 0.112 0.215 2.001 10.215 21.452 41.874 62.584 85.657 108.254
2 0.098 0.199 2.130 10.897 19.654 38.648 61.254 75.541 108.547
3 0.096 0.194 1.891 11.874 20.154 41.258 58.541 85.244 100.257
4 0.098 0.215 1.987 9.879 21.568 42.587 61.257 78.221 92.254
5 0.088 0.216 2.068 10.125 18.368 41.241 65.874 81.299 98.555
Mean 0.098 0.208 2.015 10.598 20.239 41.122 61.902 81.192 101.573
% Nominal conc. 98.40 103.90 100.77 105.98 101.20 102.80 103.17 101.49 101.57
SD 0.009 0.010 0.090 0.807 1.331 1.489 2.663 4.391 6.909
%CV 8.79 5.04 4.46 7.61 6.58 3.62 4.30 5.41 6.80
CS = Calibration standard.
Conc. = Concentration.
Table 2b Summary of calibration curves for desmethyl mirtazapine with back calculated concentrations.
Linearity Desmethyl mirtazapine, concentration in ng/ml
CS-1 CS-2 CS-3 CS-4 CS-5 CS-6 CS-7 CS-8 CS-9
0.1 0.2 2.0 10.0 20.0 40.0 60.0 80.0 100.0
1 0.102 0.208 2.015 11.258 21.588 41.248 62.338 82.557 90.222
2 0.088 0.188 2.148 9.874 18.668 38.654 58.554 78.226 102.554
3 0.114 0.195 1.998 10.565 19.667 42.558 59.654 80.221 90.241
4 0.112 0.211 2.015 10.025 21.554 37.998 60.255 84.555 98.244
5 0.118 0.212 2.144 10.111 18.889 41.224 61.223 77.666 90.257
Mean 0.107 0.203 2.064 10.367 20.073 40.336 60.405 80.645 94.304
% Nominal conc. 106.80 101.40 103.20 103.67 100.37 100.84 100.67 100.81 94.30
SD 0.012 0.011 0.075 0.561 1.417 1.927 1.451 2.909 5.769
%CV 11.28 5.28 3.64 5.41 7.06 4.78 2.40 3.61 6.12
CS = Calibration standard.
Conc. = Concentration.
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Table 3 Intra and inter accuracy and precision for MRT.
MRT intra-assay precision and accuracy MRT inter-assay precision and accuracy
Quality-control
samples
Conc. added
(ng/ml)
Mean conc.
found (ng/ml)a
SD Precision
%CV
Accuracy
(%)
Mean conc.
found (ng/ml)b
SD Precision
%CV
Accuracy
(%)
LLOQ 0.1 0.112 0.004 3.85 112.00 0.110 0.011 10.17 110.00
LQC 0.3 0.311 0.015 4.97 103.67 0.309 0.019 6.30 103.00
MQC 30.0 29.556 2.058 6.96 98.52 29.785 3.563 11.96 99.28
HQC 75.0 78.927 3.108 3.94 105.24 77.685 3.928 5.06 103.58
Conc. = Concentration.
a Mean of six replicates.
b Mean of 30 replicates.
Table 4 Intra and Inter accuracy and precision for DMRT.
DMRT intra-assay precision and accuracy DMRT inter-assay precision and accuracy
Quality-control
samples
Conc. added
(ng/ml)
Mean conc.
found (ng/ml)a
SD Precision
%CV
Accuracy
(%)
Mean conc.
found (ng/ml)b
SD Precision
%CV
Accuracy
(%)
LLOQ 0.1 0.101 0.007 7.44 101.00 0.102 0.011 11.18 102.00
LQC 0.3 0.294 0.017 5.68 98.00 0.298 0.026 8.83 99.33
MQC 30 30.798 2.927 9.50 102.66 30.704 2.604 8.48 102.35
HQC 75 72.946 4.773 6.54 97.26 76.051 3.267 4.30 101.40
Conc. = Concentration.
a Mean of six replicates.
b Mean of 30 replicates.
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(30.0 ng/ml) and HQC, (75.0 ng/ml) each on the same analyt-
ical run. Inter-assay precision and accuracy was calculated
after repeated analysis in three different analytical runs. The
results are given in Tables 3 and 4.
3.2.6. Matrix effect
Matrix effects were investigated for six different samples of
plasma comprising four lots of normal control heparinzed
plasma, one lot of lipemic plasma, and one lot of haemolyzed
plasma. Three samples each at the LQC and HQC levels were
prepared from different lots of plasma (i.e. a total of 36 QC
samples) and checked for accuracy, to see whether the matrix
affected the back-calculated value of the nominal concentra-
tions for these different plasma samples. The results obtained
were well within the acceptable limit of ±15%, which clearly
proves that elution of endogenous matrix peaks in the dead
volume time does not affect the pattern of elution of MRT,
DMRT and IS, respectively.Table 5 Stability results of MRT.
Stability experiments Storage conditions
Bench top Room temperature (12 h)
Process (extracted sample) Auto sampler (58 h)
Freeze and thaw stability in plasma After fourth FT cycle at 70 C
Long-term stability in plasma For 68 days at 70 C
LQC= 0.300 ng/ml; MQC= 30.000 ng/ml; HQC= 75.000 ng/ml.3.2.7. Stability
Exhaustive experiments were performed to assess the stability
of MRT, DMRT in stock solution and in plasma samples un-
der different conditions simulating the conditions occurring
during analysis of study samples––room-temperature stability,
extracted sample stability (process stability), freeze–thaw sta-
bility, and long-term stability of plasma samples. The results
obtained were well within acceptable limits. IS stock solution
was also found to be stable.
Stock solutions of MRT, DMRT and IS were stable at
room temperature for 20 h and at 2–8 C for 28 days. MRT
and DMRT in control human plasma were stable for 12.0 h
at room temperature. Both the analytes in extracted plasma
samples were stable for 58 h in an autosampler at 10 C.
MRT and DMRT were found stable at least four freeze–thaw
cycles. MRT and DMRT spiked plasma samples stored at
70 C to test long-term stability were stable for at least
68 days. Percentage changes of concentration in these stability
experiments are listed in Tables 5 and 6.Mean comparison
sample conc.
found (ng/ml)
Mean stability
sample conc.
found (ng/ml)
% Mean change at
quality control level
0.325 0.315 LQC 3.08
71.354 75.584 HQC 5.93
0.289 0.302 LQC 4.50
78.254 71.354 HQC 8.82
0.311 0.324 LQC 4.18
79.354 78.548 HQC 1.02
0.314 0.328 LQC 4.46
29.252 27.554 MQC 5.80
71.258 78.321 HQC 9.91
Table 6 Stability results of DMRT.
Stability experiments Storage conditions Mean comparison
sample conc.
found (ng/ml)
Mean stability
sample conc.
found (ng/ml)
% Mean change at
quality control level
Bench top Room temperature (12 h) 0.295 0.278 LQC 5.76
74.254 76.584 HQC 3.14
Process (extracted sample) Auto sampler (58 h) 0.333 0.324 LQC 2.70
71.541 78.354 HQC 9.52
Freeze and thaw stability in plasma After fourth FT cycle at 70 C 0.302 0.321 LQC 6.29
78.654 71.241 HQC 9.29
Long-term stability in plasma For 68 days at 70 C 0.325 0.311 LQC 4.31
30.254 33.255 MQC 9.92
71.354 75.554 HQC 5.89
LQC= 0.300 ng/ml; MQC= 30.000 ng/ml; HQC= 75.000 ng/ml.
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The design of study comprised an open randomized, two period,
two sequence, replicate, crossover, comparative evaluation of rel-
ative bioavailability of test formulation (TorrentPharmaceuticals
Ltd.) of mirtazapine with reference (Novartis Pharma 30 mg
Remeron, tablets) in 18 healthy adult human subjects under
fasting condition. The age of volunteers were ranged from 18
to 45 years. All the subjects were informed of the aim and risk
involved in the study and written consent was obtained. Ethics
committee approved the study protocol. The study was con-
ducted strictly in accordance with guideline laid down by Inter-
national Conference on Harmonization and USFDA (FDA
Guidance for Industry: Bioavailability Studies for orally
Administered Drug-Product – General Consideration, US
Department of Health and Human Services, Food and Drug
Administration Centre for Drug Administration Centre for
Drug Evaluation and Research (CDER, 2000)). Health check
up for all subjects was done by general physical examination,
ECG and laboratory tests like hematology, biochemistry andFigure 6 Representative chromatograms for: (a) mirtazapine; (b)urine examination. All subjects were negative for HIV, HBSAg
and HCV tests. They were orally administered a single dose of
test and reference formulation after recommended with 240 ml
of water. Drinking water was not allowed and supine position
was restricted 2 h post dose. Standardized meals were provided
as per schedule. Blood samples were collected in vacutainers
containing heparin before collection of each time point’s
administration of drug. Plasma samples were collected 0.00,
0.20, 0.40, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 6.00, 9.00,
12.00, 18.00, 24.00, 48.00, and 72.00 h after administration of
a single oral dose of a 30-mg tablet to 18 male volunteers in
each phase. Blood samples were centrifuged at 3500 rpm for
10 min and plasma was separated, stored at 70 C until use.
5. Application of method
The proposed validated method was successfully applied for
the assay of MRT and DMRT in 18 healthy adult male human
subject samples who received 30 mg of mirtazapine tablet un-
der fasting condition. A total of 1120 plasma samples fromdesmethyl mirtazapine after 3.0 h dosing and (c) extracted IS.
Figure 7 Mean plasma concentration and time proﬁle for mirtazapine and desmethyl mirtazapine.
Rapid quantiﬁcation of mirtazapine and desmethyl mirtazapine in human plasma by LC–ESI-MS/MS 15318 volunteers were analyzed along with CS’s and QC samples.
A total 560 samples were analyzed per day. The concentration
of MRT and DMRT in volunteer samples observed about
3.0 h after dosing (Fig. 6). Thus the assay procedure for
MRT and DMRT in plasma samples demonstrated the linear-
ity, precision and sensitivity needed for the pharmacokinetic
studies of this drug. The mean plasma concentration of
MRT and DMRT are shown in Fig. 7.
6. Conclusion
The objective of this work was to develop a simple, speciﬁc,
rugged and a high throughput method for simultaneous esti-
mation of MRT and its active metabolites DMRT in human
plasma. The advantage of using an SPE technique in the pres-
ent work is due to: (i) minimize the sample extraction time, (ii)
present method has been used only 200 ll of human plasma
compare to reported methods and hence to reduce the amount
of blood withdrawn from volunteers during study, (iii) signiﬁ-
cant reduction in the labor commonly associated with LLE
technique on account of ﬂash freezing of aqueous part, (iv) be-
cause of rapid sample preparation technology and short chro-
matographic run time, large numbers of pharmacokinetic
samples can be analyzed. Moreover, the limit of quantiﬁcation
is low enough to monitor at least ﬁve half life of MRT and
DMRT with good intra and inter-assay reproducibility
(%CV) for the quality control. From the results of validation
parameters, the method can be useful for therapeutic drug
monitoring both for analysis of routine samples of a single
dose or multiple dose pharmacokinetic and also for the clinical
trial samples with desired precision and accuracy.
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